What is one of the main consequences of streptokinase's non-specific lysis activity?

Streptokinase is a thrombolytic agent used in the management of conditions such as acute myocardial infarction. Its mechanism of action involves the activation of plasminogen to plasmin, which then breaks down fibrin, leading to the dissolution of clots. One of the main consequences of this non-specific lysis activity is the degradation of fibrinogen, which is a key protein involved in the coagulation process. When streptokinase acts non-specifically, it can also lead to the breakdown of fibrinogen, reducing its availability for the formation of future clots.

This aspect is particularly important because while thrombolysis is beneficial in treating existing occlusions, the degradation of fibrinogen can lead to an increased risk of bleeding. Thus, while streptokinase effectively dissolves harmful clots, it disrupts the normal hemostatic balance by lowering fibrinogen levels, which plays a critical role in maintaining coagulation. Understanding this consequence is essential for managing patients treated with streptokinase, as it helps healthcare providers anticipate potential side effects and complications associated with its use.